The challenge
A pharmaceutical company preparing to launch a first-to-market topical treatment for psoriasis in a new indication faced the challenge of developing clinical guidelines. These guidelines needed to evaluate evidence supporting various monotherapies and combination regimens to ensure the treatment’s integration into clinical practice.
Our solution
To address this, we conducted a comprehensive review of all approved topical agents used in psoriasis care, including corticosteroids, calcineurin inhibitors, vitamin D analogues, and retinoids. Leveraging this data, we developed treatment recommendations aligned with current evidence. Collaboration with the National Psoriasis Guidelines Committee and other guideline networks allowed us to assess the strength of evidence and validate findings. Using this foundation, we facilitated the development of a consensus proposal for long-term disease management.
Outcomes
Therapeutic Landscape Analysis
Established a strategic understanding of the psoriasis therapeutic landscape and desired clinical outcomes to guide a focused literature review.
Expert Collaboration
Presented a comprehensive research document with relevant findings to a panel of physicians and advanced practice providers (APPs).
National Recommendations
Led the collaborative development of national clinical guidelines for psoriasis management, incorporating both monotherapy and combination regimens.
Consensus for Long-Term Care
Successfully communicated a consensus proposal for the use of topicals in managing psoriasis over the long term.
Key takeaway
By aligning scientific evidence with clinical expertise, this initiative not only supported the successful launch of a novel topical treatment but also advanced national guidelines, enhancing psoriasis care for patients across the country.
This engagement was delivered through our tactical execution services.